Retension Pharmaceuticals, Inc. (RTSN) stock
RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.01−0.88 (-6.34%)
Close on Nov 19, 2026Market cap $10.51MP/E –Yield –
Retension Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for Retension Pharmaceuticals
Retension Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?